唑来膦酸注射液治疗恶性肿瘤骨转移疼痛50例  

A clinical study for zoledronic acid in the relief of pain due to metastatic bone malignancy

作　　者：郑荣生[1] 秦凤展[1] 陈振东[2] 熊福星[2] 

机构地区：[1]蚌埠医学院附属医院肿瘤内科,蚌埠233004 [2]安徽医科大学附属医院肿瘤内科,合肥230022

出　　处：《中国新药杂志》2005年第2期214-216,共3页Chinese Journal of New Drugs

摘　　要：目的:评价唑来膦酸注射液治疗恶性肿瘤骨转移所致疼痛的疗效和安全性。方法:100例恶性肿瘤骨转移患者,随机分为试验组50例和对照组50例。试验组用唑来膦酸注射液4mg加入生理氯化钠溶液50mL中,静脉滴注15min;对照组用帕米膦酸二钠注射液90mg加入生理氯化钠溶液500mL中,静脉滴注6h。两组均一次性给药后观察28d。结果:治疗骨转移疼痛试验组有效率为66.6%,对照组为62.3%,两组疗效差异无显著性(P>0.05)。两组不良反应发生率分别为46.0%和44.0%,差异无显著性。两组不良反应均为Ⅰ和Ⅱ度,无需特殊处理。结论:唑来膦酸注射液治疗恶性肿瘤骨转移所引起的疼痛安全有较。Objective: To evaluate the safety and efficacy of zoledronic acid to relieve pain due to metastatic bone malignancy. Methods: 100 patients with metastatic bone cancer were randomized 1∶1 to infuse intravenously either zoledronic acid (4mg, treatment group) for 15 minutes or pamidronate (90mg, control group) for 6 hours. The efficacy was observed in 28 days post drug therapy. Results: Patients in treatment group showed an overall response rate of 66.0%, compared with 62.0% in control group (P>0.05). No significant difference was found in the incidence rate of adverse reactions (grade Ⅰ/Ⅱ)(46.0% versus 44.0%, respectively, P>0.05). Conclusion: Zoledronic acid certainly has potential as an alternative therapy in the pain relief due to metastatic bone cancer.

关 键 词：唑来膦酸注射液 帕米膦酸二钠 骨转移疼痛 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]